Neurodegenerative Disease Pathology

Core Idea

Neurodegenerative diseases involve progressive neuron loss. Alzheimer's features amyloid-β plaques and tau tangles; Parkinson's involves α-synuclein inclusions and nigrostriatal dopamine loss; ALS involves motor neuron degeneration and TDP-43 pathology. Common themes include protein misfolding, aggregation, impaired clearance, and neuroinflammation.

How It's Best Learned

Study histology showing protein aggregates. Analyze genetic risk factors using GWAS databases.

Common Misconceptions

One protein causes neurodegeneration—multiple pathways converge. Neuroinflammation is a consequence—it may also drive pathology.

Explainer

From your study of protein folding and chaperones, you know that proteins must adopt specific three-dimensional shapes to function, and that molecular chaperones help them fold correctly. Neurodegenerative diseases are, at their core, diseases of protein homeostasis — conditions where misfolded proteins accumulate, aggregate, and eventually kill neurons. The specific protein differs by disease, but the underlying logic is hauntingly similar across all of them.

In Alzheimer's disease, two proteins go wrong. Amyloid-β (Aβ) is a small peptide cleaved from a larger membrane protein (APP) by enzymes called secretases. Normally, Aβ is produced and cleared without issue. But when production exceeds clearance — due to genetic mutations, aging, or impaired disposal mechanisms — Aβ monomers aggregate into oligomers, then fibrils, and finally into the dense extracellular amyloid plaques visible on brain histology. The oligomeric (small aggregate) forms appear most toxic, disrupting synaptic function before plaques even form. The second protein, tau, normally stabilizes microtubules inside axons — think of it as the railroad ties holding neuronal transport tracks together. In Alzheimer's, tau becomes hyperphosphorylated, detaches from microtubules, and aggregates into intracellular neurofibrillary tangles. The loss of microtubule stability disrupts axonal transport, and the tangles themselves are cytotoxic. Tau pathology correlates more closely with cognitive decline than amyloid burden.

Parkinson's disease involves a different protein — α-synuclein — and a different vulnerable population of neurons: the dopaminergic neurons of the substantia nigra pars compacta. α-Synuclein normally functions at presynaptic terminals, possibly regulating vesicle dynamics. When it misfolds, it aggregates into inclusions called Lewy bodies. The progressive loss of nigrostriatal dopamine neurons produces the hallmark motor symptoms: tremor, rigidity, and bradykinesia. In ALS (amyotrophic lateral sclerosis), the misfolded protein is often TDP-43, which normally shuttles between the nucleus and cytoplasm to regulate RNA processing. When TDP-43 mislocalizes to the cytoplasm and aggregates, motor neurons in the cortex and spinal cord degenerate, leading to progressive paralysis.

What unifies these diseases is a set of converging pathological mechanisms. Protein misfolding and aggregation overwhelm the cell's clearance systems — the proteasome and autophagy pathways that you encountered when studying chaperones. Neuroinflammation amplifies the damage: microglia and astrocytes, which you may know from studying glia, become chronically activated, releasing pro-inflammatory cytokines that are themselves neurotoxic. Critically, neuroinflammation is not merely a bystander response — it actively drives disease progression, creating a vicious cycle where dying neurons release debris that further activates glia. Finally, many of these misfolded proteins exhibit prion-like spreading: aggregated α-synuclein or tau can template the misfolding of normal copies in neighboring cells, causing pathology to propagate through neural circuits in predictable anatomical patterns. This spreading explains why neurodegeneration is progressive and why symptoms worsen over time — the disease follows the brain's own wiring.